Quantcast

Latest Mapatumumab Stories

2012-04-04 20:22:32

Data indicative of targeting ability of BIND-014 for high tumor drug concentration BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting....

2012-04-03 09:00:10

The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. This was evaluated using a measure termed progression-free survival (PFS). According to the results of a multi-center Phase II clinical trial, patients receiving the combination of gemcitabine and TH-302 demonstrated a progression-free survival of 5.6 months compared to 3.6 months...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related